Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SanBio Co ( (JP:4592) ) has shared an announcement.
SanBio Co., Ltd. announced the recording of significant non-operating expenses and deferred income taxes in the third quarter of the fiscal year ending January 31, 2026. The company reported a foreign exchange loss of 395 million yen and a foreign currency translation adjustment of 405 million yen due to exchange rate fluctuations, impacting its financial performance. Additionally, SanBio recognized deferred tax liabilities, leading to deferred income taxes of negative 446 million yen, affecting its earnings performance.
The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1010.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd. operates in the biotechnology industry, focusing on developing regenerative cell medicines. The company is known for its innovative treatments aimed at neurological disorders and other medical conditions, positioning itself as a leader in regenerative medicine.
YTD Price Performance: 119.31%
Average Trading Volume: 2,911,653
Technical Sentiment Signal: Sell
Current Market Cap: Yen128.5B
For an in-depth examination of 4592 stock, go to TipRanks’ Overview page.